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Impact of Bordetella pertussis Exposures
on a Massachusetts Tertiary Care Medical System
Iva Zivna, MD; Diana Bergin, MS, APRN BC;
Joanne Casavant, MS, APRN BC; Sally Fontecchio, RN, BSNEd, CIC;
Susan Nelson, RN, MSPH, CIC; Anita Kelley, RN, MSN, CIC; Sandra Mathis, RN, MPH, CIC;
Zita Melvin, RN, BSN, CIC; Rosemarie Erlichman, RN, BSN, CIC; Richard T. Ellison III, MD
objective. To assess the impact of outbreaks of Bordetella pertussis infection on a tertiary care medical system.
design. Retrospective study.
setting. Academic tertiary care medical center and affiliated ambulatory care settings.
subjects. All patients and healthcare workers (HCWs) who were in close contact with patients with laboratory-confirmed cases of B.
pertussis infection from October 1, 2003, through September 30, 2004.
intervention. Direct and indirect medical center costs were determined, including low and high estimates of time expended in the
evaluation and management of exposed patients and HCWs during outbreak investigations of laboratory-confirmed cases of B. pertussis
infection.
results. During this period, 20 primary and 3 secondary laboratory-confirmed cases of B. pertussis infection occurred, with 2 primary
pertussis cases and 1 secondary case occurring in HCWs. Outbreak investigations prompted screening of 353 medical center employees.
Probable or definitive exposure was identified for 296 HCWs, and 287 subsequently received treatment or prophylaxis for B. pertussis
infection. Direct medical center costs for treatment and prophylaxis were $13,416 and costs for personnel time were $19,500-$31,190.
Indirect medical center costs for time lost from work were $51,300-$52,300. The total cost of these investigations was estimated to be
$85,066-$98,456.
conclusions. Frequent B. pertussis exposures had a major impact on our facility. Given the impact of exposures on healthcare institutions,
routine vaccination for HCWs may be beneficial.
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Despite effective childhood immunization, pertussis remains
endemic in the United States. The incidence of pertussis has
remained high in children 1-5 years old1,2; however, evidence
is increasing that Bordetella pertussis is also an important
pathogen among adolescent and adult populations.3-9 Fur-
thermore, it is apparent that adolescents and adults with per-
tussis represent a significant source for transmission of B.
pertussis to infants younger than 4 months, resulting in in-
creasing morbidity and mortality in this age group.10
Pertussis is a remarkably contagious disease, transmitted
by aerosolized droplets, with secondary attack rates of 50%-
100% in close contacts, depending on the nature of the
exposure.11,12 It thus represents a major challenge in health-
care settings, and during the last decade, numerous noso-
comial outbreaks of pertussis have been reported.13-18 Un-
fortunately, these outbreaks not only represent a medical risk
for patients but also can significantly strain healthcare insti-
tution resources. In this retrospective study, we sought to
determine the impact of B. pertussis outbreaks on our health-
care system during 1 fiscal year, at a time when there was a
notable increase in pertussis cases in our state.
methods
Study Design and Period
A pertussis investigation was initiated at the University of
Massachusetts Memorial Medical Center (UMMMC) when-
ever a laboratory-confirmed case of pertussis was recognized.
For this report, all data from the UMMMC infection control
and employee health departments were retrospectively re-
viewed to identify the number of screened, exposed, and
treated patients and healthcare workers (HCWs) who un-
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derwent evaluation from October 1, 2003, through September
30, 2004.
Definitions
Pertussis cases were defined based on the criteria of the Mas-
sachusetts Department of Public Health.19 A clinical case of
pertussis was defined as an acute cough illness that lasted 14
days or longer in a person with at least 1 symptom charac-
teristic of pertussis (eg, paroxysmal cough, inspiratory whoop,
or posttussive vomiting) or cough that persisted for more
than 14 days during an outbreak. A confirmed case of per-
tussis met the clinical case definition and was confirmed if
culture of a nasopharyngeal swab specimen or serologic anal-
ysis was positive for B. pertussis or if there was epidemiologic
linkage to a laboratory-confirmed case. A person with a con-
firmed case of B. pertussis was considered to be infectious
from 1 week before until 3 weeks after the onset of typical
paroxysmal cough.
Screening was performed by reviewing the work schedules
of all healthcare employees who were identified as having a
potential exposure to the patient or HCW with confirmed
pertussis. All individuals who were potentially exposed were
questioned about exposure to the index patient and whether
they had any signs or symptoms suggestive of pertussis. Em-
ployees were considered to be exposed to a confirmed case
of pertussis if they had direct face-to-face contact with the
case subject while not wearing a surgical mask; spent more
than 10 hours per week in the same general work station or
area with the case subject; came into mucosal contact with
the respiratory, oral, or nasal secretions of an individual with
confirmed pertussis; or were present and not wearing a sur-
gical mask during a cough-inducing procedure for an indi-
vidual with confirmed pertussis.
Exposed screened HCWs were the subset of screened
HCWs who reported a history of exposure to a patient or
other HCW with pertussis. Unexposed screened HCWs were
the subset of screened HCWs without exposure to an index
case of pertussis.
The time needed for screening and exposure evaluation
was assessed retrospectively by interviewing all personnel as-
signed to screening- and exposure-related activities. Because
there was variation in the estimates of the time taken for
these investigations, high and low time estimates for each of
the aspects of the outbreak investigation were developed, as
follows. For the infection control department, the time for
the initial diagnostic workup was 2 hours plus 0.05 hour (low
estimate) or 0.1 hour (high estimate) per screened HCW, and
for the unit manager, the time for the initial diagnostic
workup was 2 hours plus 0.25 hour or 0.5 hour per screened
HCW. For the employee health department, the time spent
was 2 hours plus 0.25 hour or 0.5 hour per screened unex-
posed HCW and was 2 hours plus 0.5 or 0.75 hour per 0.5
hour per screened exposed HCW. For screened HCWs, the
time lost from work was 0.1 hour or 0.25 hour per screened
unexposed HCW and was 0.5 hour or 0.75 hour per screened
exposed HCW. All screened symptomatic HCWs who had
been exposed to a patient with a confirmed case of B. pertussis
infection within the previous 21 days were evaluated by cul-
ture of a nasopharyngeal swab specimen and placed on med-
ical leave for 5 days while undergoing therapy with antibiotics.
Direct medical center costs associated with pertussis out-
breaks were calculated as the cost of antibiotics needed for
prophylaxis or therapy for exposed medical center employees
and the cost of the time of designated personnel assigned to
these outbreaks. The cost of nasopharyngeal culture, includ-
ing the cost of swabs, laboratory supplies, and the time of
UMMMC laboratory personnel needed for evaluation, were
estimated to be $15–$25 per culture.
Indirect medical center costs were calculated as the number
of hours of lost employee time associated with the process
of screening, evaluation of exposures, and work missed by
exposed HCWs placed on temporary medical leave. These
costs included the cost of the replacement worker needed to
take the place of a symptomatic HCW on medical leave.
results
From October 1, 2003, through September 30, 2004, there
were 20 primary and 3 secondary laboratory-confirmed cases
of pertussis at UMMMC (Table). Two primary cases and 1
secondary case occurred among employees of our facility. The
source of infection for the 2 primary cases among HCWs
could not be identified. Outbreak investigations prompted
the screening of 353 HCWs who were potentially in close
contact with individuals who had laboratory-confirmed cases
of pertussis. Exposure was identified for 296 screened HCWs,
and 287 of them subsequently received treatment or pro-
phylaxis for pertussis infection. This resulted in an estimated
1,034-1,118 hours of time lost from work and 389-604 hours
of intensive work by staff in infection control, employee
health, and unit management.
Direct medical center costs included treatment and pro-
phylaxis (287 prescriptions), which cost $13,416, and the es-
timated time of the personnel assigned to these outbreaks
(389-604 hours) at a cost of $19,500-$31,190. The estimated
cost of laboratory testing (23 nasal swab specimen cultures)
was unremarkable at $330-$550, and serologic testing (9 B.
pertussis immunoglobulin G antibody tests) was performed
by the Massachusetts Department of Public Health laboratory
at no cost to our institution but with an estimated cost of
$520-$800.
Indirect medical center costs included 23 exposed and
symptomatic HCWs being placed on medical leave, resulting
in 880 hours of lost time from work. An additional 154-238
hours were included in time missed from work for screening
or evaluation of exposure, making the estimated total cost of
time lost from work $51,300-$52,300.
The cost to UMMMC of these investigations is estimated
to have been $84,546-$97,656 (Table). Including the cost of
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the serologic testing, the estimated total cost of the investi-
gations was $85,066-$98,456.
discussion
After introduction of the whole-cell pertussis vaccine in 1947,
the incidence of pertussis significantly decreased. Still, the
infection has remained endemic, with cyclic increases noted
every 2-5 years, suggesting that the vaccine has controlled the
disease but not eradicated circulation of the pathogen. In fact,
the number of cases of B. pertussis infection in the United
States has been rising, although vaccine efficacy has appeared
to be good.1,10,20 Of note, numerous states reported particu-
larly high levels of pertussis during calendar year 2004.
The transmissibility of pertussis is highest at the catarrhal
stage before the onset of paroxysmal cough, and it gradually
decreases until it is negligible approximately 3 weeks after the
onset of symptoms. The symptoms of pertussis may vary in
severity from a mild upper respiratory tract infection to the
full-blown syndrome, and rapid diagnostic testing is not read-
ily available. Also, many cases of pertussis occur in previously
vaccinated persons because of waning immunity. All of these
factors contribute to the difficulty of managing pertussis in
healthcare settings, locations where infection control mea-
sures need to be especially rigorous to protect individuals at
high risk of complications.
In our institution, all persons with suspected cases of per-
tussis were promptly isolated and placed under droplet pre-
cautions until they had completed 5 days of an appropriate
course of antibiotic therapy. Prompt epidemiologic investi-
gations were initiated to identify exposed HCWs and patients,
and as appropriate, were performed in coordination with the
Massachusetts Department of Public Health. All symptomatic
HCWs exposed to individuals with confirmed cases of B.
pertussis infection during the period of communicability (21
days or less after the onset of cough) were tested and excluded
from work until they had completed 5 days of an appropriate
course of antibiotic therapy; if they were not treated, they
were excluded from work for 3 weeks after cough onset. All
asymptomatic exposed HCWs who did not receive antibiotic
prophylaxis were excluded from work for 21 days after their
last exposure or, if the time of exposure was unknown, for
21 days after the onset of the last confirmed case of pertussis
in the facility.21
Our approach of investigating all cases of pertussis for
potential transmission within the institution may be consid-
ered relatively aggressive. However, during the past several
years, an increasing number of pertussis outbreaks have oc-
curred in healthcare facilities,14-16 and the approach that was
undertaken was in accordance with guidelines from the Mas-
sachusetts Department of Public Health.19
In this study, we found that implementing these guidelines
for the evaluation of B. pertussis exposures had a major impact
on our facility. The impact on the infection control, employee
health, and unit management staff was particularly significant,
functionally representing 3-6 weeks of full-time effort for 1
infection control staff member, 1 employee health staff mem-
ber, and 1 unit manager.
The direct medical center costs were estimated to be
$64,716-$65,716, which does not include the indirect medical
center cost of time lost from work because of screening and
evaluation of exposed HCWs. Having HCWs placed on med-
ical leave also represented a significant expense.
The retrospective nature of this study may have led to
overestimation or underestimation of the time and expense
involved in screening and exposure evaluation. We tried to
overcome this limitation by developing high and low time
estimates for each aspect of the outbreak investigations. Ad-
ditionally, only partial data were available on patient expo-
sures, because several of the exposures took place in waiting
areas and it was not possible to identify all of the exposed
individuals. However, a minimum of 200 patients were de-
termined to have been exposed, and they each received a
letter about potential exposure.
Given the increasing number of pertussis cases being seen
nationally and the impact of pertussis exposures on healthcare
institutions, routine vaccination for HCWs may be beneficial
in decreasing the number of HCWs who develop the disease.22
However, as highlighted in this study, many of the exposures
in healthcare settings are linked to illness in patients. Because
the institutional expense for the work involved in outbreak
investigations is significant, a key area for future study is
determining whether immunizing HCWs can obviate the
need for antibiotic prophylaxis or exclusion from work in
this population.
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